AbbVie (GB:0QCV)
LSE:0QCV

AbbVie (0QCV) Stock Price & Analysis

2 Followers

0QCV Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$131.61 - $169.42
Previous Close$157.58
Volume138.32K
Average Volume (3M)136.17K
Market Cap
$279.57B
Enterprise Value$333.50B
Total Cash (Recent Filing)$9.23B
Total Debt (Recent Filing)$63.27B
Price to Earnings (P/E)23.8
Beta0.34
Apr 27, 2023
5.78 (3.67%)
Share Statistics
EPS (TTM)6.63
Shares Outstanding1,764,141,787
10 Day Avg. Volume167
30 Day Avg. Volume136,166
Standard Deviation0.10
R-Squared0.00891
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-3.39
Price to Sales (P/S)2.42
Price to Cash Flow (P/CF)11.30
P/FCF Ratio20.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.74
Enterprise Value/Gross Profit8.21
Enterprise Value/Ebitda13.80
Forecast
Price Target Upside3.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14


Financials

Annual

0QCV FAQ

What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $131.61 and its highest was $169.42 in the past 12 months.
    What is AbbVie’s market cap?
    Currently, no data Available
    When is AbbVie’s upcoming earnings report date?
    AbbVie’s upcoming earnings report date is Apr 27, 2023 which is in 26 days.
      How were AbbVie’s earnings last quarter?
      AbbVie released its earnings results on Feb 09, 2023. The company reported $3.6 earnings per share for the quarter, beating the consensus estimate of $3.561 by $0.039.
        Is AbbVie overvalued?
        According to Wall Street analysts AbbVie’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does AbbVie pay dividends?
          AbbVie pays a Quarterly dividend of $1.48 which represents an annual dividend yield of 3.67%. See more information on AbbVie dividends here
            What is AbbVie’s EPS estimate?
            AbbVie’s EPS estimate is $2.56.
              How many shares outstanding does AbbVie have?
              AbbVie has 1,769,400,000 shares outstanding.
                What happened to AbbVie’s price movement after its last earnings report?
                AbbVie reported an EPS of $3.6 in its last earnings report, beating expectations of $3.561. Following the earnings report the stock price went up 2.259%.
                  Which hedge fund is a major shareholder of AbbVie?
                  Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 218M.

                    ---

                    AbbVie Stock Smart Score

                    The AbbVie Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    AbbVie

                    AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

                    ---

                    Forecast EPS vs Actual EPS


                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    AbbVie
                    Amgen
                    Gilead Sciences
                    Vertex Pharmaceuticals
                    Regeneron

                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis